[go: up one dir, main page]

AR022204A1 - COMPOUND, PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITION AND EDIBLE PRODUCT THAT UNDERSTANDS IT. - Google Patents

COMPOUND, PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITION AND EDIBLE PRODUCT THAT UNDERSTANDS IT.

Info

Publication number
AR022204A1
AR022204A1 ARP000100030A ARP000100030A AR022204A1 AR 022204 A1 AR022204 A1 AR 022204A1 AR P000100030 A ARP000100030 A AR P000100030A AR P000100030 A ARP000100030 A AR P000100030A AR 022204 A1 AR022204 A1 AR 022204A1
Authority
AR
Argentina
Prior art keywords
compound
understands
preparation
pharmaceutical composition
edible product
Prior art date
Application number
ARP000100030A
Other languages
Spanish (es)
Original Assignee
Norgine Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9900413.7A external-priority patent/GB9900413D0/en
Priority claimed from GBGB9917294.2A external-priority patent/GB9917294D0/en
Application filed by Norgine Bv filed Critical Norgine Bv
Publication of AR022204A1 publication Critical patent/AR022204A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

El uso de un compuesto que comprende a la formula (1): o su sal, éster, amida o prodroga para la manufactura de un medicamento para la inhibicion de unaenzima cuyo modo de accion preferido es catalizar la hidrolisis de una funcionalidad éster, por ejemplo, para el control e inhibicion de las enzimas nodeseadas en los productos y procesos. Los compuestos también son utiles en la medicina, por ejemplo, para el tratamiento de la obesidad y condicionesrelacionadas. La invencion también se refiere acompuestos de la formula (1), a los procesos para prepararlos y a las composiciones farmacéuticas que loscontienen.The use of a compound comprising the formula (1): or its salt, ester, amide or prodrug for the manufacture of a medicament for the inhibition of an enzyme whose preferred mode of action is to catalyze the hydrolysis of an ester functionality, for example , for the control and inhibition of enzymes nodeseadas in products and processes. The compounds are also useful in medicine, for example, for the treatment of obesity and related conditions. The invention also relates to compounds of the formula (1), the processes for preparing them and the pharmaceutical compositions containing them.

ARP000100030A 1999-01-08 2000-01-05 COMPOUND, PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITION AND EDIBLE PRODUCT THAT UNDERSTANDS IT. AR022204A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9900413.7A GB9900413D0 (en) 1999-01-08 1999-01-08 Inhibitors
GBGB9917294.2A GB9917294D0 (en) 1999-07-22 1999-07-22 Inhibitors

Publications (1)

Publication Number Publication Date
AR022204A1 true AR022204A1 (en) 2002-09-04

Family

ID=26314965

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100030A AR022204A1 (en) 1999-01-08 2000-01-05 COMPOUND, PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITION AND EDIBLE PRODUCT THAT UNDERSTANDS IT.

Country Status (24)

Country Link
US (4) US6624161B2 (en)
EP (1) EP1143977B3 (en)
JP (1) JP3822439B2 (en)
KR (1) KR100678998B1 (en)
CN (2) CN1915981B (en)
AR (1) AR022204A1 (en)
AT (1) ATE293447T1 (en)
AU (1) AU765147C (en)
CA (1) CA2359819C (en)
CH (1) CH1143977H1 (en)
DE (1) DE60019555C5 (en)
DK (1) DK1143977T3 (en)
ES (1) ES2240052T7 (en)
HK (2) HK1047588B (en)
HU (1) HUP0105003A3 (en)
MX (1) MXPA01006921A (en)
MY (1) MY122578A (en)
NO (1) NO333922B1 (en)
NZ (1) NZ512740A (en)
PL (1) PL207383B1 (en)
PT (1) PT1143977E (en)
RU (1) RU2245331C2 (en)
SI (1) SI1143977T1 (en)
WO (1) WO2000040247A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR022204A1 (en) * 1999-01-08 2002-09-04 Norgine Bv COMPOUND, PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITION AND EDIBLE PRODUCT THAT UNDERSTANDS IT.
GB0001572D0 (en) 2000-01-24 2000-03-15 Alizyme Therapeutics Ltd Inhibitors
US6504028B2 (en) * 2000-07-11 2003-01-07 The Procter & Gamble Co. Process for preparing benzoxazin-4-one polymer conjugates
AU2002331064B2 (en) 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
AU2002321536B2 (en) * 2001-08-30 2007-05-17 Norgine Bv Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity
CN1620439A (en) 2001-12-20 2005-05-25 Osi药物公司 Pancreatic lipase inhibitor compounds, their synthesis and use
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
CA2530634A1 (en) * 2003-06-12 2004-12-23 Menachem Rubinstein Methods of treating obesity and related disorders using tellurium and selenium compounds
GB0319124D0 (en) * 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
US20050239859A2 (en) * 2003-09-03 2005-10-27 Solvay Pharmaceuticals Gmbh Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity
US20050124660A1 (en) * 2003-10-27 2005-06-09 Jochen Antel Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
US20050143441A1 (en) * 2003-10-27 2005-06-30 Jochen Antel Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
WO2006045799A2 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
US20090082435A1 (en) * 2005-04-28 2009-03-26 The Regents Of The University Of California Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders
JP5044398B2 (en) * 2005-06-09 2012-10-10 武田薬品工業株式会社 Solid preparation
JP2010254623A (en) * 2009-04-24 2010-11-11 Takeda Chem Ind Ltd Crystal of benzoxazinone compound
PL2575768T3 (en) 2010-05-24 2018-07-31 Swedish Oat Fiber Ab Aqueous dispersion comprising galactolipids and method for production thereof
AU2012101841A4 (en) * 2011-12-23 2013-01-17 Norgine Bv Compositions comprising cetilistat
WO2013092786A1 (en) 2011-12-23 2013-06-27 Norgine B.V. Compositions comprising cetilistat
DE202012104963U1 (en) 2012-12-19 2013-01-14 Norgine B.V. Cetilistat containing compositions
CN103936687B (en) * 2014-03-24 2016-03-30 重庆东得医药科技有限公司 A kind of west of preparing is for the method for Li Sita
CN104374836A (en) * 2014-09-19 2015-02-25 安徽安科生物工程（集团）股份有限公司 HPLC determination method for Cetilistat and related impurities
CN105622538B (en) * 2014-10-27 2019-02-01 中国医学科学院药物研究所 One kettle way prepares Cetilistat in high yield
CN104341370B (en) * 2014-11-11 2017-02-22 山东创新药物研发有限公司 Preparation method of cetilistat
CN105669585A (en) * 2016-01-06 2016-06-15 北京修正创新药物研究院有限公司 Preparation method of cetilistat
CN105566164A (en) * 2016-01-06 2016-05-11 北京修正创新药物研究院有限公司 Preparation method of cetilistat impurity
WO2018011676A1 (en) * 2016-07-11 2018-01-18 Symed Labs Limited Novel processes for the preparation of 2-oxy-benzoxazinone derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE246996C (en)
US4657893A (en) 1984-05-09 1987-04-14 Syntex (U.S.A.) Inc. 4H-3,1-benzoxazin-4-ones and related compounds and use as enzyme inhibitors
US4745116A (en) 1985-06-25 1988-05-17 Syntex (U.S.A.) Inc. 2-oxy-4H-3,1-benzoxazin-4-ones and related compounds and pharmaceutical use
US4665070A (en) * 1985-06-25 1987-05-12 Syntex (U.S.A.) Inc. 2-oxy-4H-3,1-benzoxazin-4-ones and pharmaceutical use
DD246996A1 (en) * 1986-02-26 1987-06-24 Univ Leipzig PROCESS FOR PREPARING, IF NECESSARY, SUBSTITUTED 2-ALKOXY-BZW. 2-aroxy-3,1-benzoxazin-4-ones
CA1309556C (en) * 1987-06-09 1992-10-27 Masayuki Kokubo 4h-3,1-benzoxazin-4-one compounds and pharmaceutical composition thereoffor the inhibition of serine proteases
US5652237A (en) 1994-09-09 1997-07-29 Warner-Lambert Company 2-substituted-4H-3, 1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement C1r protease for the treatment of inflammatory processes
US5985872A (en) * 1995-05-24 1999-11-16 G.D. Searle & Co. 2-amino-benzoxazinones for the treatment of viral infections
US5776756A (en) * 1995-08-31 1998-07-07 Toyo Hakko Co., Ltd. Fermentation compositions having superoxide dismutating activity and an antihypertensive agent for treatment of constipation each having the superoxide dismutating activity
US6139833A (en) * 1997-08-08 2000-10-31 Lexicon Genetics Incorporated Targeted gene discovery
US6136566A (en) * 1996-10-04 2000-10-24 Lexicon Graphics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US6207371B1 (en) * 1996-10-04 2001-03-27 Lexicon Genetics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US6130214A (en) * 1997-10-27 2000-10-10 Dr. Reddy's Research Foundation Benzothiazin and benzoxazin derivatives; their preparation and uses
US6080576A (en) * 1998-03-27 2000-06-27 Lexicon Genetics Incorporated Vectors for gene trapping and gene activation
AR022204A1 (en) 1999-01-08 2002-09-04 Norgine Bv COMPOUND, PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITION AND EDIBLE PRODUCT THAT UNDERSTANDS IT.

Also Published As

Publication number Publication date
DE60019555C5 (en) 2009-07-09
HK1103928A1 (en) 2007-12-28
CN1915981A (en) 2007-02-21
AU765147B2 (en) 2003-09-11
AU765147C (en) 2007-05-31
US20080161301A1 (en) 2008-07-03
NZ512740A (en) 2003-10-31
US7825113B2 (en) 2010-11-02
HK1047588A1 (en) 2003-04-24
US20030195206A1 (en) 2003-10-16
ATE293447T1 (en) 2005-05-15
RU2245331C2 (en) 2005-01-27
NO333922B1 (en) 2013-10-21
EP1143977A1 (en) 2001-10-17
HUP0105003A3 (en) 2004-11-29
HK1047588B (en) 2007-08-24
EP1143977B1 (en) 2005-04-20
ES2240052T7 (en) 2013-02-14
US20030027821A1 (en) 2003-02-06
NO20013381L (en) 2001-09-07
JP2002534388A (en) 2002-10-15
US20110065697A1 (en) 2011-03-17
NO20013381D0 (en) 2001-07-06
AU1884600A (en) 2000-07-24
CN1359378A (en) 2002-07-17
JP3822439B2 (en) 2006-09-20
DE60019555T2 (en) 2006-02-23
US6624161B2 (en) 2003-09-23
CH1143977H1 (en) 2007-02-15
WO2000040247A1 (en) 2000-07-13
US8877750B2 (en) 2014-11-04
SI1143977T1 (en) 2005-08-31
CA2359819A1 (en) 2000-07-13
WO2000040247A9 (en) 2002-10-24
KR20020000542A (en) 2002-01-05
CN1315813C (en) 2007-05-16
DK1143977T3 (en) 2005-08-15
HUP0105003A2 (en) 2002-06-29
MXPA01006921A (en) 2003-06-04
EP1143977B3 (en) 2012-10-24
MY122578A (en) 2006-04-29
US7858617B2 (en) 2010-12-28
KR100678998B1 (en) 2007-02-07
DE60019555D1 (en) 2005-05-25
PT1143977E (en) 2005-08-31
CA2359819C (en) 2008-08-12
ES2240052T3 (en) 2005-10-16
PL207383B1 (en) 2010-12-31
CN1915981B (en) 2011-09-28
WO2000040247A8 (en) 2001-02-15

Similar Documents

Publication Publication Date Title
AR022204A1 (en) COMPOUND, PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITION AND EDIBLE PRODUCT THAT UNDERSTANDS IT.
HUP0201343A2 (en) Hypolipidemic benzothiazepine compounds, process for their preparation and pharmaceutical compositions containing them
HUP0000838A2 (en) Extract containing steroid-glucosid, process for its isolation and synthesis, pharmaceutical composition containing it having appetite suppressant activity
UA42734C2 (en) Water-soluble nimesulide salt, aqueous solution thereof, nimesulide-based compositions, process for preparation of nimesulide salt, pharmaceutical composition the treatment of inflammations
AU2267395A (en) Benzofuran derivatives useful as inhibitors of bone resorption
RU94027576A (en) Derivatives of 1-benzenesulfonyl-1,3-dihydro-indole-2-on, method for their production and pharmaceutical compositions containing them
PT1274698E (en) PERCYCININE, METHOD FOR PRODUCING AND USING IT AS A MEDICINAL PRODUCT
HUP0100178A2 (en) Tetrahydro-naphtiridinyl-imidazolydinyl-carboxylic acid derivatives and pharmaceutical compositions thereof
FI19992360A (en) Product and process for its preparation
PT915898E (en) CLARITROMYCIN CRYSTALLINE I FORM
HUP0300826A2 (en) Polymorphs of an epothilone analog, process for their preparation and pharmaceutical compositions containing them
BG106389A (en) Crystals of the sodium salt of pravastatin
BR0014939A (en) Oligosaccharides, oligosaccharide preparation process, pharmaceutical compositions, and use of oligosaccharides
FR2743075B1 (en) PROCESS FOR THE PREPARATION OF ACTIVE SUBSTANCES FROM NACRE, PRODUCTS OBTAINED, USEFUL IN PARTICULAR AS MEDICAMENTS
HUP9904634A2 (en) Thiazolidine-derivatives, process for their preparation pharmaceutical compositions containing the same and intermediates
CN100361987C (en) ascorbic acid compound, synthesis method and application thereof
CA2211320A1 (en) 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
AU1466295A (en) Amino acid derivatives and their use as phospholipase a2 inhibitors
ES2173195T3 (en) ANTHRACICLINE DERIVATIVES.
NO951532D0 (en) Tilidine dihydrogen orthophosphate, process for its preparation and pharmaceutical compositions containing the compound
ES2127278T3 (en) PREPARED OF 2-ARYL-PROPIONIC ACIDS AND PROCEDURE FOR THEIR PRODUCTION.
IL82523A0 (en) Microbicidal compositions,their manufacture and drugs containing them
DK1123937T3 (en) Substance GM-95, process for its preparation and use thereof
PT1218401E (en) 4-BENZYLAMINOQUINOLINS CONTAINED WITH BILIARY ACID AND ITS HETEROCYCLICS METHODS OF THEIR PRODUCTION MEDICINES CONTAINING THESE COMPOUNDS AND ITS APPLICATION
NO307933B1 (en) Water-insoluble or slightly water-soluble therapeutic compound, use thereof as well as pharmaceutical mixture containing said compound

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee